Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2010 5
2011 33
2012 75
2013 118
2014 111
2015 171
2016 145
2017 151
2018 161
2019 76
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

935 results
Results by year
Filters applied: . Clear all
Page 1
Antibody humanization methods - a review and update
Safdari Y, et al. Biotechnol Genet Eng Rev 2013 - Review. PMID 24568279
Common methods for producing humanized antibodies including framework-homology-based humanization, germline humanization, complementary determining regions (CDR)-homology-based humanization and specificity determining residues (SDR) grafting, as well as advantages and disadvantages of each of these methods and their applications are discussed....
Common methods for producing humanized antibodies including framework-homology-based humanization, germline humanization, comp …
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Lee JY, et al. Nat Commun 2016. PMID 27796306 Free PMC article.
In recent years, the blockade of checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has enabled the development of breakthrough therapies in oncology, and four therapeutic antibodies targeting these checkpoint molecules have been approved by the FDA for the treatment of several types of cancer. ...These complex structures elucidate the precise epitopes of the antibodies and the molecular mechanisms underlying checkpoint blockade, providing useful information for the improvement of monoclonal antibodies capable of attenuating checkpoint signalling for the treatment of cancer....
In recent years, the blockade of checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has enabled t …
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Fessas P, et al. Semin Oncol 2017 - Review. PMID 28923212 Free PMC article.
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)-targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. ...Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. ...
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)-targeted antibodies
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt JW, et al. Sci Rep 2018. PMID 29686315 Free PMC article.
Direct comparative studies with analogs of gantenerumab, bapineuzumab and solanezumab demonstrate clear differentiation in the binding properties of these antibodies. ...Our studies provide a structural rationale for the low affinity of aducanumab for non-pathogenic monomers and its greater selectivity for aggregated forms than is seen for other Aβ-targeting antibodies....
Direct comparative studies with analogs of gantenerumab, bapineuzumab and solanezumab demonstrate clear differentiation in the binding prope …
Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Huang S, et al. MAbs 2018. PMID 30081724 Free PMC article.
MBS301 consists of two half antibodies engineered from trastuzumab and pertuzumab, respectively. Integrity and purity profiles of MB301 indicated that the heterodimerization of the two half antibodies was successful. The high and similar melting temperatures (Tm1,72.0°C and Tm2, 84.8°C) of MBS301 compared with those of its parental monoclonal antibodies trastuzumab and pertuzumab (in-house made T-mab and P-mab, respectively) revealed its structural compactness. ...
MBS301 consists of two half antibodies engineered from trastuzumab and pertuzumab, respectively. Integrity and purity profiles of MB3 …
Mechanically interlocked functionalization of monoclonal antibodies.
Bzymek KP, et al. Nat Commun 2018. PMID 29679060 Free PMC article.
Because monoclonal antibodies (mAbs) have exceptional specificity and favorable pharmacology, substantial efforts have been made to functionalize them, either with potent cytotoxins, biologics, radionuclides, or fluorescent groups for therapeutic benefit and/or use as theranostic agents. ...To further extend the lifetime of the complex, we created a mechanical bond by incorporating an azide on the meditope, threading the azide through the Fab, and using click chemistry to add a steric group. ...
Because monoclonal antibodies (mAbs) have exceptional specificity and favorable pharmacology, substantial efforts have been ma …
Antibody-drug conjugates: current status and future directions
Perez HL, et al. Drug Discov Today 2014 - Review. PMID 24239727
Antibody-drug conjugates (ADCs) aim to take advantage of the specificity of monoclonal antibodies (mAbs) to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells. ...
Antibody-drug conjugates (ADCs) aim to take advantage of the specificity of monoclonal antibodies (mAbs) to deliver potent cyt …
Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples.
Zhang YF and Ho M. MAbs 2017. PMID 28165915 Free PMC article.
Rabbit monoclonal antibodies (RabMAbs) can recognize diverse epitopes, including those poorly immunogenic in mice and humans. ...Using this strategy, we humanized 4 RabMAbs that recognize poorly immunogenic epitopes in the cancer target mesothelin. Three of the 4 humanized rabbit Fvs have similar or improved functional binding affinity for mesothelin-expressing cells. ...
Rabbit monoclonal antibodies (RabMAbs) can recognize diverse epitopes, including those poorly immunogenic in mice and humans. …
935 results
Jump to page
Feedback